Tests for candidiasis

PreclinicalBiologic

CCentre Hospitalier Universitaire de Nīmes

Tests for candidiasis is one of 7 biologic programs targeting Candidiasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CandidiasisActive, not recruiting

CandidiasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Candidiasis

#DrugCompanyPhaseTrials

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

15 2

Mycamine

BBaxter Healthcare Corporation

Approved

12 3

Cancidas

FFresenius Kabi Taiwan Ltd.

Approved

7 4

Eraxis

VVicuron Pharmaceuticals

Approved

4 5

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

2 6

Vfend

PPrism Pharmaceuticals

Approved

2 7

Tests for candidiasis

CCentre Hospitalier Universitaire de Nīmes

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Candidiasis1 trial

Staging Candidiasis in ICU Patients

Completed·—··NCT01322698·422 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tests for candidiasis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tests for candidiasis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tests for candidiasis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire de Nīmes company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentre Hospitalier Universitaire de Nīmes

Tests for candidiasis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Candidiasis1 trial

References

Drug Info

Quick Facts

Related News